Early diagnostics of prostate cancer based on a comprehensive analysis of risk factors

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: There is a trend of increasing incidence and mortality from prostate cancer. Existing methods for early diagnosis and screening of prostate cancer did not demonstrate enough efficiency.

AIM: To improve the quality and efficiency of diagnostic measures for prostate cancer through a personalized approach to patients based on an analysis of a set of risk factors.

MATERIALS AND METHODS: The methodology was developed using the data from the population-based Cancer Registry of the Altai Territory, created at the Altai Regional Oncology Center in Barnaul, Russia. At the moment the Cancer Registry included information on 308 550 patients with malignant neoplasms, including 15 167 males with prostate cancer. On the basis of the method of prostate cancer risk assessment proposed by Lazarev AF an automated program for early diagnosis of prostate cancer has been developed. Testing of this technique included assessment of 532 patients (aged between 23 and 82).

RESULTS: 128 patients were determined to belong to the high risk pre-cancer group. A high-risk precancer registry was created, which included the patients having individual risk of developing prostate cancer either increased or high or absolute. Upon a set of in-depth examinations, 7 of 128 patients (9.3%) were diagnosed with prostate cancer, all at early stages (I or II). Thus, the incidence of prostate cancer among the patients from the high risk pre-cancer registry was significantly higher than the average observed during prophylactic examinations (0.01%).

CONCLUSION: The automated program for early diagnosis of prostate cancer could be implemented with the aim to assign in-depth examination in more targeted manner to patients at high risk of prostate cancer and to contribute to detection the cancer in the early stages.

全文:

受限制的访问

作者简介

Alexander Lazarev

Altai State Medical University

Email: lazarev@akzs.ru
ORCID iD: 0000-0003-1080-5294
俄罗斯联邦, Barnaul

Valentina Petrova

Altai State Medical University

Email: valent_04@mail.ru
ORCID iD: 0000-0001-7169-9646
俄罗斯联邦, Barnaul

Sergey Lazarev

Altai State Medical University

Email: serglazarev@bk.ru
ORCID iD: 0000-0001-7748-0784
俄罗斯联邦, Barnaul

Tatiana Repkina

Altai State Medical University

Email: k-polter@asmu.ru
ORCID iD: 0000-0003-4583-313X
Barnaul

Svetlana Terekhova

Altai State Medical University

编辑信件的主要联系方式.
Email: quip@list.ru
ORCID iD: 0009-0001-4594-4529

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Barnaul

Pavel Obеremok

Consultative Diagnostic Center of the Altai Territory

Email: pasha22ru@mail.ru
ORCID iD: 0009-0002-3250-6914
俄罗斯联邦, Barnaul

Ilya Osipov

Medical Institute named after Berezin Sergey

Email: osipov_1989@bk.ru
ORCID iD: 0009-0008-4560-2933
俄罗斯联邦, Barnaul

Maria Nikolaeva

Altai State Medical University

Email: k-ginek@asmu.ru
ORCID iD: 0000-0001-9459-5698
俄罗斯联邦, Barnaul

Dmitriy Ganov

Altai State Medical University

Email: ganovdmit@yandex.ru
ORCID iD: 0000-0002-7118-1668
俄罗斯联邦, Barnaul

参考

  1. Surveillance, Epidemiology, and End Results Program. Prostate cancer. USA: National Cancer Institute. [cited 01 Jan 2023]. Available from: http://www.seer.cancer.gov
  2. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
  3. Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: P.A. Herzen MNIOI — branch of FGBU NMC Radiology of the Ministry of Health of Russia; 2022. (In Russ).
  4. Kaprin AD, Starinskii VV, Shakhzadova AO, editors. State of oncological care for the Russian population in 2022. Moscow: P.A. Herzen MNIOI — branch of FGBU NMC Radiology of the Ministry of Health of Russia; 2023. (In Russ).
  5. Sergeeva NS, Skachkova TE, Marshutina NV, Alekseev BYa, Kaprin AD. Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. Onkologiya. Zhurnal im. P.A. Gertsena. 2018;7(1):55–67. EDN: YRTOMF doi: 10.17116/onkolog20187155-67
  6. Pushkar’ DYu, Rasner PI. Differential diagnosis of cancer and benign prostatic hyperplasia. Russian Medical Journal. 2014;22(17):1298–1303. (In Russ). EDN: SKBOXD
  7. Prostate cancer. Clinical guidelines. ID 12. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2021. Available from: https://cr.minzdrav.gov.ru/recomend/12_3
  8. Patent RUS № 2692987/ 28.06.2019. Lazarev AF. Method for determining the risk of prostate cancer. (In Russ).
  9. Certificate of state registration of the computer program № 2019663514/ 17.10.2019. Lazarev AF, Pokornyak VP, Marchkov VA, Lazarev SA, Petrova VD. Automated program for early diagnosis of prostate cancer (PC). (In Russ).
  10. Certificate of state registration of the computer program №2008611703/ 31.03.2008. Lazarev AF. Territorial Cancer Registry (In Russ).

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Access to the “Automated program for early diagnosis of prostate cancer”: QR code.

下载 (58KB)

版权所有 © Eco-Vector, 2023



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г
.



##common.cookie##